Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   17/09/2026
39,19 USD (+1,71%)
(+1,71%)   17/09/2026
Grafiek Teva- Pharmaceutical Industries Ltd. Grafiek Teva- Pharmaceutical Industries Ltd.

Teva- Pharmaceutical Industries Ltd. in het nieuws

16 september 2026 · Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care · Persbericht

14 september 2026 · Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy · Persbericht

10 september 2026 · Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes · Persbericht

7 september 2026 · Teva Announces Launch of Offering of Senior Notes · Persbericht

4 september 2026 · S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline · Persbericht

2 september 2026 · Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential · Persbericht

1 september 2026 · Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September · Persbericht

31 augustus 2026 · Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S. · Persbericht

28 augustus 2026 · Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy  · Persbericht

19 augustus 2026 · U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome · Persbericht

Profiel Teva- Pharmaceutical Industries Ltd.

Fabricage van farmaceutische preparaten
Farmaceutische Producten: Generisch
Gezondheidstechnologie
Productie

Mijn selecties